SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (20700)5/13/1998 5:18:00 PM
From: celeryroot.com  Read Replies (1) | Respond to of 32384
 
F, maybe you better read again and research what your saying more carefully



To: Hippieslayer who wrote (20700)5/13/1998 5:54:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
FUGAZI, When I figured out that the LLY drug was a SRGN compound, it wasn't much of a leap to figure out that the specialty cancer company was SRGN (which I posted last year).



To: Hippieslayer who wrote (20700)5/13/1998 6:12:00 PM
From: Peter Silsbee  Respond to of 32384
 
>> It's like negotiating a car deal and finding out that the deal you agreed to with the slick sales man actually is more money than you had agreed to.

Maybe, but he also threw in a couple of extra cars.

Repeat to yourself: two separate deals. Two separate deals. Two separate deals.

PLS


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News